Palo Alto, United States
BioMap, founded in 2020, is an innovative player in the convergence of AI and Life Sciences. Under the inspirational banner of "Decoding life with AI Foundation Models," the United States-based company is at the vanguard of generating proteins for therapeutic and industrial applications.
With the backing of strategic collaborations, most notably with Baidu, BioMap leverages unparalleled computational power to build super-scale foundation models. This synergy is reinforced by the shared vision of its Founder and Chairman, Robin Li. The company boasts a robust team of scientists and disease experts, whose work in high-throughput labs supplies critical proprietary data to fuel their cutting-edge AI models.
Through flexible collaboration models, BioMap partners with pharmaceutical firms and biotech players alike, driving discoveries across diverse therapeutic and synthetic biology domains. This unique approach has attracted significant investor interest, with the most recent $20.00M early VC investment made in June 2024 by the Hong Kong Investment Corporation. BioMap aims to harness AI to significantly improve human life, offering partners a competitive edge in the ever-evolving life sciences landscape.
